Newsroom

Jun 15, 2026 FungiFlex New Journal of Fungi Publication Features Zepto FungiFlex® in Pneumocystis Case Series A University of Minnesota collaboration examines how plasma fungal cfDNA testing can help distinguish active infection from colonization in complex, immunocompromised patients. → Jun 3, 2026 FungiFlex Zepto Life Technology Receives FDA Breakthrough Device Designation for Targeted Liquid Biopsy Test for Invasive Mold Infections The designation applies to the FungiFlex® Mold Panel performed on Zepto's integrated MDx instrument system, recognizing its potential to address a significant unmet need in invasive mold infection diagnosis. → Jan 21, 2026 FungiFlexReference lab Zepto Life Technology Launches Plasma-Based FungiFlex® Mold Panel as CLIA Reference Laboratory Test The plasma-based test becomes commercially available for the first time, detecting 14 clinically important mold species in under 24 hours. → Jan 5, 2026 Team Zepto Life Technology Welcomes Dr. David S. Perlin to our Advisory Board The globally recognized biomedical scientist and Journal of Fungi Editor-in-Chief joins Zepto's Medical & Technical Advisory Board. → Mar 16, 2025 Investors Zepto Life Technology Showcases Transformative Diagnostic Platform at LSI USA 2025 Zepto presents its GMR biosensor platform to investors and industry leaders shaping the future of healthcare. → Feb 25, 2025 FungiFlex Zepto Publishes Breakthrough Culture-Free Diagnostic Approach for Invasive Fungal Infections in Open Forum Infectious Diseases The study introduces a rapid molecular platform for detecting fungal cell-free DNA, offering an alternative to conventional culture-based diagnosis. → Jan 17, 2025 Investors Walleye Tank Pitch Contest Awards Zepto with Top Prize for Innovative Fungal Diagnostic Platform Hosted by Mayo Clinic and the University of Minnesota, the win recognizes Zepto's GMR-based diagnostic system. → Jan 14, 2025 Investors Zepto Life Technology Presents at J.P. Morgan 2025 Healthcare Conference and Engages with Global Leaders in Medical Innovation Zepto engages with global investors and strategic partners on faster, more accurate infectious disease diagnostics. → Jun 14, 2024 FungiFlex Zepto Life Technology’s New Publication: cfDNA and GMR Technology in the Journal of Fungi A University of Minnesota collaboration explores GMR-based cfDNA detection for monitoring fungal infection response to therapy. → Mar 14, 2024 MDx Zepto Life Technology Showcase at European Congress of Clinical Microbiology and Infectious Disease Conference Presented with Mayo Clinic in Barcelona, the study details a multiplex GMR and lab-on-a-chip assay for invasive fungal infection diagnosis. → Feb 14, 2024 Team Zepto Life Technology Builds Medical & Technical Advisory Board MTAB A distinguished board of infectious disease, cfDNA, and regulatory experts is formed to guide Zepto's scientific direction. → Jan 14, 2024 MDx Zepto Life Technology Showcase at Advances Against Aspergillosis Conference Presented in Milan, the abstract details detection of Aspergillus fumigatus cell-free DNA using GMR technology. → Dec 14, 2023 Investors Zepto Life Technology Closes Series A Funding The round funds fabrication and testing of a fully integrated system automating the assay workflow from sample to result. → Nov 14, 2023 FungiFlex Zepto's Innovative Invasive Fungal Infection (IFI) Detection System Study Launch A collaboration with the University of Minnesota puts Zepto's primer and probe design and GMR detection to the test in clinical molecular diagnostics. → Feb 14, 2023 FungiFlex Zepto Life Launches Pilot Clinical Study with Mayo Clinic for Invasive Fungal Infection Detection Led by Dr. Vergidis, the study evaluates Zepto's diagnostic test for invasive fungal infections directly from patient blood samples. → Oct 14, 2020 Reference lab Zepto Life Stands Up Diagnostic Lab and Obtains High-Complexity CLIA Lab Certificate to Offer Diagnostic Testing Built as a COVID-19 response, the new lab supports school districts and underserved communities in Minnesota with reliable testing access. → Sep 18, 2020 Our history Zepto Life Technology Selected as Semi-Finalist for AACC's Disruptive Technology Award Competition Zepto showcases GMR-based detection of nine fungal strains responsible for 95% of U.S. fungal infections. → Sep 19, 2019 Our history Zepto Won Top Prize in the RESI Boston 2019 Innovation Challenge Zepto's lab-on-a-chip GMR platform is recognized for its versatility across immunoassay and molecular targets. →